Phase 2 N=35 Phase II Trial of Continuation Therapy in Advanced NSCLC
Non-Small-Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 5.1 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
Postbariatric Hypoglycemia
Primary: Postprandial Glucose Nadir — 57.1; 59.2; 47.1 mg/dL
Phase 2 N=9 Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
Non-Small-Cell Lung Carcinoma · Carcinoma, Non-Small Cell Lung
Primary: Identification of Safe-dose for the Phase 2 Double-blind Phase in the Lead-in Phase — 10 milligrams (mg)
Phase 2 N=32 Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Phase 2 N=96 RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT) — 9; 5; 4; 2 Participants
Phase 2 N=98 A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Primary: Relapse-free Survival (RFS) Per Independent Review Committee (IRC) Adjudication — 24.02; 15.84 Months — p=0.163
Phase 2 N=45 Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Primary: Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) Score — -5.5; -6.0; -3.2 score on a scale — p==0.0941
Phase 2 N=3 Exenatide for Treating Cocaine Use Disorder
Cocaine Use Disorder
Primary: Feasibility as Assessed by Number of Participants Who Completed Treatment — 3 Participants
Phase 2 N=10 Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B
Hemophilia B
Primary: Number of Participants With Adverse Events — 5; 5 participants
Phase 2 N=38 ET-01 in Subjects With Lateral Canthal Lines, LCL-209
Lateral Canthal Lines, LCL · Crow's Feet
Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 3; 1…
Phase 2 N=11 A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 2 Participants
Phase 2 N=75 Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
Actinic Keratosis
Primary: Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months — 59.1; 72.5 Percent change of AK lesions
Phase 2 N=25 Decitabine and Talazoparib in Untreated AML and R/R AML
Acute Myeloid Leukemia
Primary: Phase 1 - Dose Finding — 10; 15; 20; 20 mg/m^2
Phase 2 N=117 Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis
Osteoarthritis
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -2.04; -2.00 score on a scale
Phase 2 N=136 Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
Obesity
Primary: Gastric Emptying of Solids (T1/2) — 191.6; 105.9 minutes